BIOGEN INC.

Biogen Inc. discovers, develops, manufactures, and delivers therapies across the United States, Europe, Germany, Asia, and internationally. The company offers treatments for multiple sclerosis (MS), including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI. For spinal muscular atrophy, it provides SPINRAZA, and SKYCLARYS is available for Friedreich's Ataxia. QALSODY treats amyotrophic lateral sclerosis, and FUMADERM is used for plaque psoriasis. Biogen also offers biosimilars: BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. The company's portfolio includes LEQEMBI for Alzheimer's disease and ZURZUVAE for postpartum depression. Oncology and immunology products include RITUXAN for non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA is for non-Hodgkin's lymphoma and CLL, while GAZYVA treats CLL and follicular lymphoma. OCREVUS is available for relapsing MS and primary progressive MS. LUNSUMIO treats relapsed or refractory follicular lymphoma, and glofitamab is for relapsed or refractory diffuse large B-cell lymphoma, alongside other anti-CD20 therapies. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. The company has collaboration and license agreements with various entities, including Merz Therapeutics, Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., UCB, Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis, and Sage Therapeutics, Inc. It also collaborates with Stoke Therapeutics, Inc. for zorevunersen, Dayra Therapeutics, Inc. for oral macrocyclic peptides, Vanqua Bio, Inc. for a preclinical oral C5aR1 antagonist compound, City Therapeutics, Inc. for novel RNAi therapies, and ALTEOGEN Inc. for subcutaneous (SC) formulations of biologics utilizing ALT-B4.